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BGC9331 is a rationally designed, specific nonpolyglutamatable thymidylate synthase (TS) inhibitor that is active in gynaecological
malignancies. In the light of the sensitivity of human ovarian tumour cell lines to BGC9331 and non-cross resistance to platinum drugs,
we studied the combination BGC9331/carboplatin (BCA) in a phase I (PI) pharmacokinetic (PK) and pharmacodynamic (PD) study in
platinum pretreated gynaecological malignancies. Patients were X18years or over, with a histologically confirmed gynaecological
malignancy, radiological evidence of relapse, and a platinum treatment free interval of at least 6 months. Up to three prior lines of
chemotherapy were permitted. Carboplatin (AUC5) and BGC9331 were administered on day 1, and BGC9331 was also given on
day 8 of a 21-day cycle. In total, 14 patients were enrolled, and treated with BGC9331 at four dose levels, 40, 65, 85 and 100mgm
 2.
The principal grade 3 and 4 haematological toxicity was neutropaenia. The principal nonhaematological toxicities were lethargy and
nausea. Dose-limiting toxicities were seen in two patients at 100mgm
 2 BGC9331 (grade 4 neutropaenia 47 days, and grade 4
fatigue 47 days). Plasma BGC9331 was measured by an ELISA that was adapted for use in humans. Carboplatin was assayed by
flameless atomic absorption spectrometry. There was no PK interaction between the two drugs. Plasma deoxyuridine was elevated
indicating TS inhibition to at least day 12. Antitumour activity was observed in four out of 14 (28%) of patients. In conclusion, the
combination of BGC9331 and carboplatin is well tolerated with no significant PK interaction between the two drugs. There is
evidence of TS inhibition with the combination. We have demonstrated antitumour activity in platinum pretreated gynaecological
malignancy. Further exploration of this combination in this disease is warranted.
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BGC9331 IN OVARIAN CANCER
Ovarian cancer remains the leading cause of death from
gynaecological malignancy in the United Kingdom, affecting
approximately 6000 women per year (CRC, 2001). The overall
survival for this disease has changed little over the last few years,
with the majority of women still relapsing and dying. Significant
changes in the treatment of ovarian cancer have occurred over the
last 30 years with the introduction into clinical practice of
platinum-based regimes, and more recently in combination with
taxanes. Platinum–taxane combinations are now regarded as
standard first-line treatment of this disease. Current clinical trials
are exploring combinations of platinum and taxanes with new
agents as well as investigating sequential regimens.
BGC9331 is a rationally designed, quinazoline-based specific
inhibitor of thymidylate synthase (TS) that was developed at the
Institute of Cancer Research (ICR), Sutton, Surrey, UK in
collaboration with AstraZeneca (current drug development under
control of BTG International). It has been assessed in phase I/II
studies in a number of tumour types including ovarian cancer
(Plummer et al, 2003; Rader et al, 2003). Low clinical activity was
previously demonstrated when targeting TS in ovarian cancer with
the polyglutamatable TS inhibitor raltitrexed (RTX) demonstrating
7 and 11% response rates (Gore et al, 1995; Muggia et al, 1998),
and 5-FU a 14% response rate (Look et al, 1995) in relapsed
disease. However, there are a number of reasons why the addition
of carboplatin to the nonpolyglutamatable TS inhibitor BGC9331
warrants investigation in this disease.
Firstly, CB3717, the first specific folate-based TS inhibitor to be
developed clinically, RTX (Kelland et al, 1995) and BGC9331
(Jackman et al, 2002) have demonstrated non crossresistance to
platinum-based agents in human ovarian tumour cell lines.
Secondly, preclinical studies suggested that folyl-polyglutamate
synthase (FPGS) expression, the enzyme required for polygluta-
mation of RTX but not BGC9331, may be lower in human ovarian
tumour cell lines compared with human colorectal cancer cell lines
and BGC9331 overcomes the associated resistance to RTX in these
cells (Jackman et al, 2002). Thirdly, CB3717 demonstrated activity
in platinum-resistant ovarian cancer (Calvert et al, 1986; Clarke
et al, 1993) in phase I and phase II trials. This drug is a relatively
poor substrate for FPGS compared to RTX (Jackman et al, 1993).
Fourthly, a-folate receptor (a-FR) mediated uptake may contribute
to the activity of some antifolates, particularly BGC9331 (Theti and
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sJackman, 2004). The a-FR is overexpressed in up to 90% of
epithelial ovarian cancers (Toffoli et al, 1997). Finally, BGC9331
has demonstrated encouraging phase I and II activity in relapsed
ovarian cancer (Plummer et al, 2003; Rader et al, 2003).
BGC9331 has been combined with cisplatin in a heavily
pretreated PI population of patients with a variety of malignancies
(Bilenker et al, 2004). Carboplatin, however, has little or no
ototoxicity, neurotoxicity, nephrotoxicity and a reduced incidence
of nausea and vomiting compared with cisplatin (Calvert et al,
1985). The lack of nephrotoxicity precludes the need for prolonged
admission, allowing administration over 1h as opposed to 8–12h
for cisplatin. Other phase I combination studies with BGC9331
have been undertaken with agents with activity in ovarian cancer
(Louvet et al, 2002; Wood et al, 2002; Benson et al, 2003). This
study is the first to combine a TS inhibitor with a platinum-based
drug in ovarian cancer.
The primary aim of this study was to determine the maximum
tolerated dose (MTD) of a combination of BGC9331 and
carboplatin in platinum-sensitive gynaecological malignancies.
Rational clinical development of any new agents should include
pharmacodynamic (PD) end points, and therefore secondary aims
in this study were the pharmacokinetics (PKs) of the combination,
and the assessment of TS inhibition by measuring plasma
deoxyuridine (dUrd), a nucleotide that increases following TS
inhibition (Ford et al, 2002).
PATIENTS AND METHODS
Definitions
Dose-limiting hematological toxicities were defined as nadir
absolute neutrophil count (ANC) o0.5 10
9l
 1 for X7 days,
thrombocytopenia o25 10
9l
 1, or an ANC o0.5 10
9l
 1
associated with fever. Dose-limiting non-haematological toxicities
were defined as any grade 3 or 4 toxicity not ameliorated by
symptomatic measures or treatment delay X2 weeks.
The MTD was defined as the dose at which two or more patients
experienced dose-limiting toxicities.
Patient recruitment and eligibility
Patients were recruited from the Royal Marsden Hospital (RMH)
Gynaecological Oncology Unit between September 2000 and June
2002.
Women who were X18years, with a performance status (PS) of
0–2 and a life expectancy of 43 months were entered into the
study. Patients required histologically or cytologically confirmed
adenocarcinoma of the ovary, peritoneum or fallopian tube, mixed
mullerian tumour, or other gynaecological malignancy for which
the use of carboplatin or TS inhibitor in relapsed disease would be
considered reasonable. A platinum therapy free interval of X6
months was required prior to initiation of trial therapy. Patients
were excluded for the following reasons: progression on or within
6 months of the end of platinum treatment, no change in disease
status at the end of platinum treatment, or response after three
cycles of platinum treatment but with no further response after six
cycles.
Patients were allowed up to three prior lines of chemotherapy,
but those who had received previous or concomitant radiotherapy
were excluded. No previous exposure to TS inhibitors or previous
hormonal or chemotherapy within 4 weeks (no exposure to
nitrosureas or mitomycin C within 6 weeks) of initiation of
treatment was permitted. Minimal haematological parameters were
as follows: neutrophils X1.5 10
9l
 1, haemaglobin X9gdl
 1,
platelets X100 10
9l
 1. Adequate liver function as demonstrated
by serum bilirubin p1.25 upper limit of reference range
(ULRR), and/or alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) p5 ULRR in the presence of liver
metastases, or p2.5 ULRR in the absence of demonstrable liver
metastases. Albumin was required to be Xlower limit of normal.
Minimal renal function was a creatinine clearance (GFR) of
X60mlmin
 1, as calculated by the EDTA/Cockcroft-Gault equa-
tion. Written informed consent to participate in the trial was
obtained prior to treatment, according to guidelines set out by the
institutions ethics committee, which approved the study.
Trial design
This was a phase I dose escalation study of BGC9331 in
gynaecological malignancies with a fixed dose of carboplatin in
patients with greater than 6 months platinum free treatment
period. Three patients were planned at each dose level and the
MTD was defined as the dose at which two or more patients
experienced dose-limiting toxicities. The dose level below MTD
was to be expanded to six patients. There were six dose levels in
the trial. The carboplatin was administered at a fixed dose of
AUC5, as determined by the formula: AUC¼(glomerular filtration
rate (GFR)þ25) 5 (Calvert et al, 1989) at all dose levels. The GFR
was determined in all patients by
51CrEDTA (Chantler et al, 1969).
The planned starting BGC9331 dose was 40mgm
 2, then escalated
to 65, 85, 100 and finally 130mgm
 2, the recommended single-
agent phase II dose (Plummer et al, 2003) (Table 1). As a
precaution, a reduced BGC9331 dose level was included in the
event of severe toxicities being observed at early dose levels
(30mgm
 2). The carboplatin was administered at AUC5 on day 1
of a 21-day cycle, with BGC9331 administered on days 1 and 8 of a
21-day cycle (Figure 1).
Assessment methods
Pretreatment evaluation Patients were assessed prior to initia-
tion of therapy by physical examination and full blood count
(FBC), urea and electrolytes (U&E) and liver function tests (LFT),
computerised axial tomography (CT), serum tumour marker
measurement (CA-125), and electrocardiograph (ECG).
Table 1 Dose levels of BGC9331 and carboplatin
Dose level
BGC9331
(mgm
 2) Carboplatin
Number of
patients
 1 30 AUC 5 0
1 40 AUC 5 3
2 65 AUC 5 3
3 85 AUC 5 6
4 100 AUC 5 2
5 130 AUC 5 0
Carboplatin 
One cycle 
Week 3  Week 2  Week 1 
BGC9331
(day 8)
BGC9331
(day 1) (day 15)
Figure 1 Dose administration schedule of BGC9331 and carboplatin.
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sToxicity Following initiation of treatment an FBC was performed
weekly, with U&E and LFT and full clinical examination performed
prior to day 1 of each new cycle of chemotherapy, or when
clinically indicated. Toxicity was assessed according to NCI-
EORTC toxicity criteria, prior to each new cycle of treatment or
when clinically indicated.
Response Response was assessed radiologically following every
two cycles of chemotherapy according to WHO criteria (Miller
et al, 1981) or when clinically indicated. CA-125 was measured
prior to each new cycle of chemotherapy.
PK and PD measurements Blood was taken for carboplatin
assessment pretreatment on day 1 and then 0.5, 1, 1.5, 2, 4, 6, 9, 12,
24, 48, 72, 96 and 168h after treatment. Blood was taken for
BGC9331 pretreatment and then 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 48,
72, 96, 168, 168.5, 169, 170, 171, 172, 174, 176, 180, 192, 216, 240
and 264h following treatment. Blood was also taken for dUrd
assessment at 4, 9, 12, 24, 48, 96, 168, 192 and 264h.
Measurement of BGC9331 by ELISA
Adaptation of the ELISA assay for analysis of human plasma The
BGC9331 in this study was assayed by ELISA that has been
previously described for use with animal samples (Aherne et al,
2001). The assay has never previously been used to measure drug
levels in humans. Prior to each assay the plasma samples were
centrifuged at 3000g for 5min 2, to sediment precipitants that
would block pipette tips. Serial dilutions were 10–20 times greater
than required for measurement of drug levels in in vitro cultured
cells or in vivo mouse samples, and were selected so that at least
one dilution per sample would fall within the standard curve.
All dilutions required for the ELISA were performed by
Multiprobe II automated liquid handling equipment (Perkin-
Elmer, Cambridge, UK). In brief, 96-well microtitre plates were
coated with purified anti-BGC9331 polyclonal rabbit antibody
(ICR, batch 8768, 8769). Following the addition of standards and
patient samples, a conjugate of BGC9331 and horseradish
peroxidase was added. Following further incubation and washing
steps, the optical absorbance was read and plotted using a four-
parameter logistic curve fitted by nonlinear regression as
previously described (Aherne et al, 2001).
Measurement of carboplatin by flameless atomic
absorption spectrophotometry (FAAS)
Carboplatin was measured by FAAS. This method has been
previously described (LeRoy et al, 1977). Samples were analysed
on a Perkin-Elmer HGA800, AA300 Flameless atomic absorption
spectrophotometer, and a Platinum Lumina HCC lamp (Perkin-
Elmer, Beaconsfield, UK).
Preparation of calibration standards and quality controls
(QCs) Calibration standards were prepared individually for each
assay batch by adding Carboplatin standards to control human
plasma and ultrafiltrate. A blank was made using either plasma or
ultrafiltrate only. A range of standards was made ranging from 5 to
50ngml
 1Pt (plasma samples) to 10–150ngml
 1Pt (ultrafil-
trates).
For plasma analysis, three QCs were included in duplicate,
ranging from low (15ngml
 1Pt) to medium (25ngml
 1Pt) and
high (45ngml
 1Pt), by diluting stock solutions with plasma. For
ultrafiltrate analysis low (20ngml
 1Pt), medium (60ngml
 1Pt)
and high (120ngml
 1Pt) QCs and stock solutions were diluted
with plasma ultrafiltrate. A run was acceptable if four out of six
QCs were within 15% of nominal concentration.
Control samples were used in each batch to check for interfering
peaks of unknown origin and to measure 0ngml
 1Pt for the
calibration curve. In the light of samples from the clinical study
containing BGC9331, QCs spiked with BGC9331 were also included
to be compared to QCs without and vice versa. PK analysis was
performed using WinNonlin Software, version 3.2 (Pharsight
Corp., CA, USA). The calculation of kinetic parameters was
performed using a two- or three- compartment open model for
BGC9331, and a noncompartmental model analysis for carbo-
platin. The following PK parameters were evaluated: maximum
plasma concentration (Cmax), area under the plasma concentra-
tion–time curve (AUC), total body clearance (Cl), volume of
distribution at steady state (Vss) and the terminal half-life (t1/2).
PD assesment
High-performance liquid chromatography (HPLC) for dUrd HPLC
for dUrd and was performed using a previously defined method
(Mitchell et al, 2000). This method has a limit of quantification
of approximately 6nM. In brief, the precipitating plasma
proteins were removed by centrifugation and by the addition of
perchloric acid, centrifugation and subsequent precipitation
with 50ml5 M KOH, and 250ml3 M KHCO3. Samples were then
recentrifuged and 200mlN a 2HPO4 buffer was then added to
the supernatant. This was followed by a solid phase extraction
(SPE) step in which dUrd in the samples were eluted with
methanol in SPE columns then evaporated to dryness in a
vacuum, reconstituted in water and stored at  201C pending
analysis.
Estimation of dUrd recovery Processing losses were estimated by
adding 50ml 1/1000 diluted [5-
3H]20dUrd to triplicate 1.0ml
aliquots of normal human plasma. These samples were processed
along with plasma samples. Stocks of labelled dUrd were assayed
by HPLC every 3 months, and the value for dUrd activity was
corrected for degradative losses. The activities of the processed
standards was counted and compared to that of 50ml of the
labelled dUrd to obtain a recovery factor, which was applied to all
samples.
Data analysis The peak area of dUrd was used as the assay
parameter. A standard calibration curve was obtained from 1/x
weighted least squares regression analysis, with the quality of fit
evaluated by comparison of calculated to nominal values. Linearity
of the calibration was confirmed using the correlation coefficient
and comparison of the intercept with zero. Plasma dUrd results
were expressed as the mean of the two duplicate assays after
correction for recovery as above.
RESULTS
Patient characteristics
Demographics Patient characteristics are shown in Table 2. In
total, 14 patients were entered into the study between October 2000
and June 2002. The median age was 51 years (range 44–64). All
patients had an ECOG PS of 0 or 1 on trial entry. Pathology was
independently reviewed at the earliest possible stage of treatment
at the RMH in all but one patient. Six patients had ovarian
tumours of papillary histology, three mucinous, and of the
remaining four patients, one had endometriod, one clear cell,
one mixed mullerian and one undifferentiated tumour histology. A
total of 66 cycles of chemotherapy were administered. The median
number of cycles/patient was 6 (range 1–6). The mean number of
cycles/patient was 4.7.
Previous chemotherapy All patients had received 1–3 lines of
previous chemotherapy and had a minimum platinum free interval
of 6 months. Six patients received BCA second line. Four of
these six received carboplatin/paclitaxel (CATAX), one received
BGC9331 and carboplatin in gynaecological malignancies
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spegylated liposomal doxorubicin, carboplatin and paclitaxel
(FATCAT), and one doxorubicin, carboplatin and paclitaxel
(TCAT) as first treatment. Seven of the remaining eight patients
received BCA third line, and the eighth patient received BCA
fourth line. Prior chemotherapy regimens for these patients were
carboplatin (CA), CATAX, epirubicin, cisplatin and 5-FU (ECF),
the taxane analogue BMS184476, or single-agent liposomal
doxorubicin.
Dose escalations
Three patients were entered at dose level 1. No dose-limiting
toxicities were seen at this level. A further three patients were
entered at dose level 2. Five patients were entered at dose level 3
because the first two patients at this dose level received only day 1
of treatment due to non-treatment related complications. At dose
level 4, two out of two patients experienced dose-limiting
toxicities; therefore, dose level 3 was further expanded to a total
of six patients and further PK and PD performed on patient 6 at
dose level 3.
Dose delays
One patient at dose level 1 (BGC9331 40mgm
 2) had a 1-week
delay in chemotherapy due to asymptomatic neutropaenia.
Similarly, two patients at dose level 2 (BGC9331 65mgm
 2) had
a 1-week delay in either their 4th or 5th cycle of treatment. At the
remaining dose levels, patients had either omission of their day 8
BGC9331 or a 1-week delay in one or two of the six cycles
administered.
Toxicities
The combination was generally well tolerated. There were no
treatment-related deaths. Lethargy and nausea were the principal
non-haematological toxicities, half of the patients experienced
grade 1 or 2 lethargy and nine out of 14 patients experienced grade
1 or 2 nausea. Grade 1 or 2 alopecia occurred in 50% of patients.
Diarrhoea affected two out of 14 and mucositis two out of 14
patients, but was short lived and did not require any treatment
(Table 3). Grade 3 and 4 non-haematological toxicities were grade
3 lethargy in two patients at dose level 3 and one patient
experienced grade 3 nausea at dose level 3. At dose level 4, one
patient experienced grade 3 diarrhoea and one patient grade 4
nausea. At this dose level, one patient experienced grade 4 lethargy
47 days, which was a dose-limiting toxicity. Grade 1 or 2
neutropaenia and anaemia affected six out of 14 patients,
respectively, with grade 1 and 2 anaemia affecting four out of 14
patients. No patients required platelet support or blood trans-
fusion while on treatment.
No haematological or non-haematological grade 3/4 toxicities
were seen at dose level 1. One patient had grade 3 neutropaenia at
dose level 2. One patient had grade 3 neutropaenia at level 3. Dose-
limiting grade 4 neutropaenia was seen in one patient at dose level
4. This patient was not admitted to hospital as there were no
obvious symptoms or signs of infection, but was monitored daily
by analysis of blood parameters. The toxicity was dose limiting by
the fact that the neutropaenia was grade 4 for 410 days (Table 3).
BGC9331 PKs
No matrix effects were observed at these dilutions of drug in
human plasma. Recovery of BGC9331 fortified into normal plasma
(concentrations) was 121%. Interassay variation as determined
using a control sample included in each assay was 20.1%
(coefficient of variation). Recovery of BGC9331 from plasma was
not affected by the presence of carboplatin (data not shown). PK
measurements were performed at dose levels 1 and 2 (Figure 2).
Mean clearance and Cmax are shown in Table 4, and individual
patient PK parameters for dose level 2 are shown in Table 5.
Plasma BGC9331 levels were measured on a total of six patients at
dose level 1 and 2 during their first cycle of chemotherapy. There
was wide interpatient variability. The mean7s.d. total plasma
clearance of BGC9331 after day 1 administration at 40mgm
 2 was
478mlh
 1761.3. Following the day 8 dose the mean clearan-
ce7s.d. was 971mlh
 17265. At dose level 2 of 65mgm
 2
BGC9331, the mean7s.d. total plasma clearance of BGC9331 after
day 1 administration was 1197mlh
 17580. Following the day 8
dose the mean clearance7s.d. was 746mlh
 17584.
The mean7s.d. Cmax of BGC9331 after day 1 administration at
40mgm
 2 was 11.21mgml
 172.51. Following the day 8 dose the
mean Cmax7s.d. was 7.26mgml
 175.0. At dose level 2 of
65mgm
 2 BGC9331, the mean7s.d. value after day 1 administra-
tion was 16.54mgml
 172.4. Following the day 8 dose the mean
Cmax7s.d. was 10.36mgml
 174.0.
Carboplatin PKs
Data were unavailable for patient 2. The mean carboplatin AUC
recovered for all patients was 5.171.1. Individual AUC measured
for each patient are shown in Table 6.
Table 2 Patient characteristics
Media age (range), years 51 (44–64)
Histology Papillary 6
Mucinous 3
Endometrioid 1
Clear cell 1
Mixed mullerian 1
Undifferentiated 1
Unknown 1
Prior lines of chemotherapy One 6
Two 7
Three 1
Table 3 NCI-CTC grade 1–4 nonhaematological and haematological
toxicities by dose levels (all cycles)
Dose level
1234
Grade 1 and 2 toxicities
Lethargy 3/3 1/3 2/6 2/2
Vomiting 1/3 1/3 0/6 0/2
Nausea 2/3 3/3 2/6 2/2
Diarrhoea 0/3 0/3 2/6 0/2
Alopecia 1/3 2/3 2/6 1/2
Rash 0/3 0/3 2/6 1/2
Peripheral neuropathy 1/3 0/3 2/6 0/2
Mucositis 0/3 1/3 0/6 1/2
Anaemia 2/3 2/3 2/6 0/2
Thrombocytopaenia 0/3 1/3 1/6 2/2
Neutropaenia 1/3 1/3 2/6 2/2
Grade 3 and 4 toxicities
Lethargy 0/3 0/3 2/6 1/2
Nausea 0/3 0/3 1/6 1/2
Diarrhoea 0/3 0/3 0/6 1/2
Thrombocytopaenia 0/3 0/3 0/6 0/2
Neutropaenia 0/3 1/3 1/6 1/2
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sdUrd elevation as a PD end point of TS inhibition
Results for one patient at dose level 3 of BGC9331 85mgm
 2 have
not been included due to an error in sample preparation. There
was a very wide interpatient variability in dUrd elevation in all
patients studied (Figure 3). The mean pretreatment dUrd for all
patients was 53717nM. This is consistent with previously
published results (Plummer et al, 2003). The mean was similar
0 24 48 72 96 120 144 168 192 216 240 264
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Figure 2 BGC9331 plasma concentration (mean7s.d.mgml
 1) in three patients at dose level 2 (BGC9331 65mgm
 2).
Table 4 Mean plasma clearance and Cmax BGC9331
Dose level 1 Dose level 1 Dose level 2 Dose level 2
Day 1 Day 8 Day 1 Day 8
Median plasma clearance (mlh
 1) 478761 9717265 11977580 7467584
Median Cmax (mgml
 1) 11.272.5 7.375.0 16.572.4 10.474.0
Median plasma clearance in mlh
 17s.d. following day 1 and day 8 BGC9331 dosing at the first two dose levels in the study. The day 8 clearance at dose level 1 appears higher
than that might be expected, and is not demonstrated at dose level 2. The Cmax at dose level 2 is higher than that observed at dose level 1.
Table 5 Individual BGC9331 pharmacokinetics patients 4 to 6 at dose level 2 (BGC9331 at 65mgm
 2, carboplatin AUC 5)
Patient Administration Dose level Tmax (h) Cmax (lgml
 1) AUClast (lgmlh
 1) Vz_obs (ml) HL_Lambda_z (h) Cl_obs (mlh
 1)
4 1 2 0.5 16.8 90.4 31423.8 18.2 1197.5
2 168.5 10.4 68.4 66088.6 27.8 1646.5
5 1 2 0.5 16.6 264.6 13891.3 25.5 378.4
2 168.5 16.7 193.3 17208.1 21.7 549.2
6 1 2 0.5 12.6 66.5 101091.3 46.7 1499.8
2 168.5 9.3 141.3 30257.3 28.1 746.0
Table 6 Free carboplatin pharmacokinetics
Patient number AUC (hlgl
 1) Cmax (lgl
 1) Alpha_HL (h) Beta_HL (h) CL (lh
 1) Vss (l) V2 (l) AUC in carbo
1 29488.8 6815.3 2.2 50.3 8.7 123.3 91.2 3.4
3 55048.1 15973.2 1.2 8.2 4.8 27.1 15.1 6.3
4 46033.7 9539.7 2.4 100.9 7.0 186.5 158.5 5.3
5 54008.5 17397.3 1.5 92.0 6.0 115.6 101.0 6.2
6 42771.6 11427.8 1.8 60.4 6.7 109.7 88.9 4.9
14 38602.7 16744.5 0.4 2.6 6.1 16.5 8.6 4.5
Free carboplatin pharmacokinetics for two patients at dose level 1, three at dose level 2 and one patient at dose level 3. The figures in bold represent the measured AUC of
carboplatin in the samples.
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sfor the three patients at dose level 1 (55714nM) and dose level 2
(49725nM). A rise of dUrd to approximately 300% of baseline was
observed at dose level 1 (40mgm
 2 BGC9331) at approximately
12h (mean elevation 312% of baseline) and persisted until 48h
(180717nM, 3477136%), at the next time point (96h) the level
was lower but still above baseline (198%). At dose level 2
(65mgm
 2 BGC9331) a rise of 360% above baseline was observed
at 9h, falling to 260% at 24h and then 200% of baseline at 48h and
128% at 96h. The observed rise in dUrd above baseline 24h
following the day 8 BGC9331 dose was 225% at dose level 1 and
217% at dose level 2.
Deoxyuridine remained elevated above baseline up to 12 days
after commencement of chemotherapy. The pattern of dUrd
elevation observed is similar to that observed in previous
published data (Plummer et al, 2003), although the patient
numbers are small in this study.
Antitumour activity and biological response
In total, 14 patients had measurable metastatic disease. Four out of
14 (28%) of patients had radiological evidence of antitumour
activity. One patient had a complete response (CR) after four
cycles of BCA. This patient had one line of previous chemotherapy
and maintained a clinical and radiological remission for 4 years.
Five out of 14 (36%) patients had a 450% reduction in their
pretreatment CA-125 upon completion of treatment.
CONCLUSION
BGC9331 is a rationally designed nonpolyglutamatable specific
inhibitor of TS. It has demonstrated a wide range of antitumour
activity in vitro and in vivo (Boyle, 1999). Phase I and interim
analysis of phase II studies showed encouraging activity,
particularly in heavily pretreated ovarian cancer (Plummer et al,
2003; Rader et al, 2003). This study was based on a number of
rationales including preclinical evidence that impaired poly-
glutamation is a potential mechanism of resistance to antifolates
(Jackman et al, 1995), and data from in vitro studies suggesting a
reduced expression of FPGS in a panel of ovarian compared with
colorectal cell lines (Jackman et al, 2002). BGC9331 does not
require polyglutamation and therefore it was hypothesised that it
may overcome this mechanism of resistance. A requirement of
polyglutamation may possibly explain the poor clinical activity of
the polyglutamatable TS inhibitor RTX in ovarian cancer (Gore
et al, 1995; Muggia et al, 1998). In addition, for many solid
tumours combining agents with different modes of action and
different toxicity profiles offers the best chance of improving
efficacy.
BGC9331 has been successfully combined with a number of
agents in a phase I setting (Louvet et al, 2002; Wood et al, 2002;
Benson et al, 2003; Bilenker et al, 2004). In our study it was found
that patients only experienced dose-limiting toxicities approaching
the full single-agent dose of BGC9331. This is supported by
the relatively improved side effect profile of this combination
as compared with other BGC9331 combination studies. For
instance, when combined with topotecan at half the single-agent
dose of both drugs, a high degree of haematological and
non-hematological toxicity was observed, including a treatment
related death (Benson et al, 2003). In combination with cisplatin
the MTD was reached at 130mgm
 2 BGC9331 days 1 and 8,
and cisplatin 75mgm
 2 on day 1 of a 21-day cycle. The
predominant toxicity was grade 3 or 4 neutropaenia in three of
the four patients at this dose level (Bilenker et al, 2004).
The toxicity profile seen in our study was comparable to that
reported in the BGC9331 monotherapy studies. In particular, in
the phase II monotherapy study of BGC9331 130mgm
 2 given
day 1 and day 8 in ovarian cancer, the main grade 3 and 4
haematological toxicities were neutropaenia and thrombo-
cytopaenia, and the main non-haematological toxicities were
nausea and asthenia (Rader et al, 2003). Thrombocytopaenia and
neutropaenia were the main haematological toxicities in our study,
with nausea and fatigue being the most common nonhaemato-
logical toxicities.
Dose-limiting toxicities were seen in two patients at dose level 4
(carboplatin AUC 5, BGC9331 100mgm
 2). These were grade 4
fatigue (patient bed bound for 450% of the day) for 47 days in
one patient and grade 4 neutropaenia for 410 days. Myelosupres-
sion and fatigue are attributable to both drugs. Similar severe
toxicities were seen in other combination studies with BGC9331,
predominantly myelosupression and asthenia (Louvet et al, 2002;
Wood et al, 2002).
Diarrhoea has been a feature of previous studies affecting 36% of
patients as (Rader et al, 2003). Diarrhoea-related morbidity has
also been a concern with RTX, but only one patient experienced
grade 3 diarrhoea in our study at dose level 4 (BGC9331
100mgm
 2, carboplatin AUC5), which was self-limiting and the
patient did not require hospital admission.
PK data for BGC9331 in our study is comparable to previous
reports where the equivalent dosing schedule was administered
(Plummer et al, 2003).The AUC and Cmax for BGC9331 (Table 7) in
our study are comparable with this historical published data at
equivalent doses and schedules. However, some differences were
observed such as the lower AUC of BGC9331 of 140mghml
 1 in
our study at 65mgm
 2 compared with 322mghml
 1 at 69mgm
 2
(Plummer et al, 2003). However, the Cmax at both comparable dose
levels are similar in both studies, and the differences in AUC seen
may be due to several reasons. Different methodologies were used
in both studies (mass spectroscopy vs ELISA). The numbers of
patients and the patient population in each study differed as the
Plummer study had greater numbers and a more heavily treated
traditional phase I population. The crossreactivity of the antibody
did not lead us to believe that ELISA results should yield higher
values than mass spectroscopy.
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Figure 3 Mean dUrd for patients at dose level 2.
Table 7 Comparison of BGC9331 pharmacokinetics in BGC9331/
carboplatin study with historical data from PI BGC9331 monotherapy study
at comparable doses
BGC9331 PI monotherapy study BGC9331 and carboplatin PI study
Dose
BGC9331
(mgm
 2)
AUC
(lghml
 1)
Cmax
(lgml
 1)
Dose
BGC9331
(mgm
 2)
AUC
(lghml
 1)
Cmax
(mgml
 1)
42 176 10.4 40 110 11.21
69 322 19.1 65 140 16.54
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the target AUC5, and therefore there appears to be no PK
interaction with BGC9331 at the doses used.
In a study comparing patterns of dUrd elevation between
BGC9331 and other TS inhibitors (bolus/infusional 5-FU and
RTX), different patterns of dUrd elevation are seen. With bolus
and infusional 5-FU, smaller peaks are seen (2357125% bolus,
228786% infusional) with the latter maintained throughout the
infusional schedule. With the pure TS inhibitor RTX given on a
21-day cycle, a greater peak percentage rise is seen compared with
5-FU (3497128%) and reapproaches baseline at approximately
day 15 (Ford et al, 2002).
We have shown PD evidence of TS inhibition by the
combination of BCA. In a previous study of single agent
BGC9331 at a similar dose level (42mgm
 2 days 1 and 8), the
pattern of dUrd elevation was similar to our study, with dUrd rises
seen after day 1 and day 8 in both studies (Plummer et al, 2003).
The peak percentage rise in our study (BGC9331 at 40mgm
 2)
after day 1 was 360% (9h) compared with a peak percentage rise of
270% (72h) (Plummer et al, 2003).
Despite wide interpatient variability in published studies, we
have demonstrated similar rises in dUrd, indicating similar TS
inhibition is achieved with the combination as with other TS
inhibitors. However, as blood sampling times and patient numbers
were not identical between studies, comparisons of dUrd elevation
should be made with caution.
In the present study, there was radiological evidence of
antitumour activity in 28% of patients, and 36% of patients had
evidence of a response, as determined by falling CA-125 levels on
treatment. However, it must be noted that the clinical activity
observed in this setting may be attributable entirely to carboplatin.
The response rate in this setting for single-agent platinum treatment
ranges from approximately 19 to 30% (Gore et al, 1990; Markman
et al, 1991). While dUrd elevation is achieved in our study, the
clinical contribution of a TS inhibitor in combination would need to
be determined in a future study by randomizing patients to
carboplatin alone vs BCA. Incorporating assessment of relevant
potential predictors of response (e.g. TS gene or protein expression)
may also help to determine this contribution.
In conclusion, the combination of BGC9331 and carboplatin is
well tolerated, with no significant PK interaction between the two
drugs. There is evidence of TS inhibition with the combination and
this is consistent with previous studies. We have demonstrated
antitumour activity in platinum-sensitive relapsed ovarian cancer.
Further exploration of this combination in this disease is
warranted.
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